Kassandra Officer is an Associate with Finnegan. She focuses on patent and trade secret litigation before U.S. district courts as well as on post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). Her practice encompasses a range of technologies, with an emphasis on chemicals, pharmaceuticals, and medical devices.
Kassandra represents pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act as well as parties in trade secret misappropriation actions. Her experience covers numerous aspects of trial preparation, including conducting offensive and defensive discovery, taking and defending fact and expert depositions, managing day-to-day litigation activities, preparing for and going to trial, and drafting post-trial briefing. Kassandra has also counseled clients regarding quarantine and clean-room redesign procedures.
Kassandra represents clients in inter partes review (IPR) and other contested proceedings before the PTAB. Her experience includes developing validity positions, drafting written submissions, and preparing technical expert witnesses. Kassandra has an active patent prosecution and counseling practice, preparing and prosecuting U.S. patent applications on behalf of international clients, with a focus on chemical subject matter, including pharmaceutical and veterinary drug products.
While in law school, Kassandra worked as a legal extern for a medical device company, where she conducted patent portfolio analysis and mapped competitors’ technologies in order to formulate patent strategies. In addition, Kassandra aided in developing the Maurer School of Law Intellectual Property Clinic, where she provided patent due diligence and patent drafting services for several clients.
Kassandra’s pro bono experience includes assisting veterans with claims before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.
The U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) recently released an update to its Orange Book patent and biologic patent study, examining post-grant petitions filed against Orange Book patents and biologic patents between September 16, 2012, and June 30, 2021. The PTAB classified a petition as challenging an Orange Book-listed patent by comparing the petition’s filing date with data from the U.S. Food and Drug Administration’s (FDA’s) electronic Orange Book indicating when the patent was listed. The PTAB manually identified biologic patents as any patent potentially covering a Purple Book-listed product and any non-Orange Book-listed patent directed to treating a disease or condition.